CD19 and neoplasm: To increase specificity and reduce liver toxicity and Fc γ receptor binding, bispecific antibodies targeting both T-cells (e.g. via 4-1BB) and either tumor antigens (e.g. CD19) or tumor stroma (e.g. FAP) have been developed.